Glaxosmithkline reported $4.27B in Cash and Equivalent for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
AstraZeneca AZN:LN 6329M 738M
Aurora Cannabis Inc ACB:CN 332.4M 40.39M
Canopy Growth Corp WEED:CN C$ 193.47M 614.15M
Corcept Therapeutics CORT:US $ 77.62M 17.07M
Novartis NOVN:VX SF 12407M 5196M
Teva Pharmaceutical TEVA:IT 2.16B 120M
Valeant Pharmaceuticals VRX:CN $ 582M 108M
Zoetis ZTS:US $ 3482M 210M